Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $14 to $14.5.
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $14 to $14.5.